Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1994-03-30
1995-08-01
Lacey, David L.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
514 8, 530350, 530395, 530827, A61K 3900, C07K 1400, C07K 14435
Patent
active
054378656
ABSTRACT:
The invention is an isolated, sialylated glycoprotein, referred to as endosialin, which is expressed by tumor associated vascular endothelium and not normal vascular endothelium. The protein portion of the glycoprotein has a molecular weight of about 95 kilodaltons as determined by SDS-PAGE, and the glycoprotein has a molecular weight of about 165 kilodaltons, also as determined by SDS-PAGE. The oligosaccharides are linked by O-linkages to the protein. The glycoprotein is useful for making antibodies which are in turn used to identify tumor associated vascular endothelium.
REFERENCES:
Rettig et al. PNAS 89: 10832-10836 (1992).
Ruiter et al. J. Invest Dermatol. 93: 255-325 (1989).
Schlingemann et al. Am. J. Pathol. 138: 1335-1347 (1991).
Seed et al. PNAS 84: 3365-3369 (1987).
Garin-Chesa Pilar
Old Lloyd J.
Rettig Wolfgang J.
Gambel Phillip
Lacey David L.
Memorial Sloan-Kettering Cancer Center
LandOfFree
Isolated sialylated glycoprotein endosialin, which is expressed does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated sialylated glycoprotein endosialin, which is expressed , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated sialylated glycoprotein endosialin, which is expressed will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-732758